109 related articles for article (PubMed ID: 7641740)
1. Level of c-erbB-2 oncoprotein in the homogenate of malignant and benign breast tumor samples.
Regidor PA; Callies R; Schindler AE
Eur J Gynaecol Oncol; 1995; 16(2):130-7. PubMed ID: 7641740
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
3. Determination of cytosol c-erbB-2 protein in breast cancer by sandwich enzyme immunoassay.
Imoto S; Ohkura H; Sugano K; Sasaki Y; Ito K; Igarashi T; Ohtsu T; Fujii H; Minami H; Hasebe T; Mukai K
Jpn J Clin Oncol; 1998 Feb; 28(2):92-6. PubMed ID: 9544822
[TBL] [Abstract][Full Text] [Related]
4. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
Aryandono T; Harijadi ; Ghozali A
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
[TBL] [Abstract][Full Text] [Related]
5. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
6. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
7. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
8. Serum c-erbB-2 protein in breast cancer patients.
Chearskul S; Sinlarat P; Bhothisuwan K; Churintrapun M; Ornrhebroi S; Klinsala N; Sungkabunchoo S
J Med Assoc Thai; 2000 Aug; 83(8):886-93. PubMed ID: 10998842
[TBL] [Abstract][Full Text] [Related]
9. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.
Watanabe T; Fukutomi T; Tsuda H; Adachi I; Nanasawa T; Yamamoto H; Abe K
Jpn J Cancer Res; 1993 Dec; 84(12):1279-86. PubMed ID: 7904987
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of C-erbB-2 and hormone receptors' status in human benign and malignant breast lesions.
Goussia A; Agnantis NJ; Athanassiadou S; Stefanou D
Anticancer Res; 1995; 15(5B):2313-8. PubMed ID: 8572645
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer.
Nugent A; McDermott E; Duffy K; O'Higgins N; Fennelly JJ; Duffy MJ
Clin Chem; 1992 Aug; 38(8 Pt 1):1471-4. PubMed ID: 1353709
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer.
Shukla S; Singh BK; Pathania OP; Jain M
Indian J Med Res; 2016 May; 143(Supplement):S52-S58. PubMed ID: 27748278
[TBL] [Abstract][Full Text] [Related]
13. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
Gago FE; Tello OM; Diblasi AM; Ciocca DR
J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(4B):3091-7. PubMed ID: 9329609
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors.
Valerón PF; Chirino R; Vega V; Falcón O; Rivero JF; Torres S; León L; Fernández L; Pestano J; Díaz-Chico B; Díaz-Chico JC
Int J Cancer; 1997 Apr; 74(2):175-9. PubMed ID: 9133451
[TBL] [Abstract][Full Text] [Related]
17. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
18. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein.
Wu JT; Astill ME; Gagon SD; Bryson L
J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455
[TBL] [Abstract][Full Text] [Related]
19. Immunostaining of estrogen receptor, progesterone receptor, MIB1 antigen, and c-erbB-2 oncoprotein in cytologic specimens: a simplified method with formalin fixation.
Suthipintawong C; Leong AS; Chan KW; Vinyuvat S
Diagn Cytopathol; 1997 Aug; 17(2):127-33. PubMed ID: 9258620
[TBL] [Abstract][Full Text] [Related]
20. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
